MSF Science Portal
My saved items
Conference Material > Slide Presentation
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
Solomos A,
Musa AM,
Mbui J,
Mohammed R,
Olobo J,
Ritmeijer KKD,
Alcoba G,
Muthoni Ouattara G,
Egondi T,
Nakanwagi P,
Omollo T,
Wasunna M,
Alvar J,
Alves F
Download
View
Share
Linked Items
Share
Download
Countries
Ethiopia
Kenya
Uganda
Sudan
Subject Area
pediatrics
neglected tropical diseases
kala azar
leishmaniasis
DOI
10.57740/81jj-tz57
Published Date
07-Jun-2023
Languages
English
Conference
MSF Scientific Days International 2023
Linked Items
Previous
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
07-Jun-2023
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
07-Jun-2023
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
07-Jun-2023
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
07-Jun-2023
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
07-Jun-2023
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
07-Jun-2023
Next
